Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X:
“More evidence of the benefit of CDK4/6i in HER2+ MBC seen in a phase 2 study of TD-M1 plus Palbociclib.
Palbociclib benefit was independent of ER status when combined to TD-M1.”
Antonio Giordano shared results from a phase 2 study evaluating the combination of TD-M1 and Palbociclib in HER2-positive metastatic breast cancer. The findings suggest that the clinical benefit of Palbociclib was not influenced by estrogen receptor status.
More posts featuring Antonio Giordano.
